Meeting News

Model predicts 80% of patients with Crohn’s at risk for complications

CHICAGO — The PROSPECT model predicted more than 80% of patients with Crohn’s disease have a moderate to high risk of developing related complications within 3 years of analysis, according to data presented at Digestive Disease Week.

“As we know, Crohn’s disease is a chronic, destructive disease that causes irreversible bowel damage in many patients,” Corey A. Siegel, MD, MS, from the Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, said during the presentation. “While damage typically happens early, there is a window of opportunity to prevent disease progression. We can get the right patients the right medications at the right time and we can prevent these complications from recurring over a period of time.”

Corey A. Siegel, MD, MS

Corey A. Siegel

The ongoing prospective study recruited 154 patients within 15 years of diagnosis of Crohn’s disease with no current or prior disease complications. Currently, 124 patients have been followed for 1 year. Median patient age is 31 years (range, 18-69 years) and 51% were women.

The PROSPECT tool uses serologic and genetic testing, disease phenotype and demographic information to generate an individualized risk profile. Patients either had a low risk of developing disease-related complication (17%), moderate risk (58%) or high risk (25%).

Twenty-one patients have experienced complications, including stricture (76%), internal penetrating (10%) or both (14%). Seven patients underwent surgery. Among the 21 patients with complications, 14% were considered low risk, 48% were considered moderate risk and 38% were considered high risk.

The study will continue for 2 years, at which time the researchers will explore how the PROSPECT tool influences patient decision making for Crohn’s disease therapy.  by Talitha Bennett

References:

Thompson KD, et al. Abstract 20. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.

Disclosure: Siegel reports he is a consultant for AbbVie, Amgen, Lilly, Janssen, Sandoz, UCB, Prometheus and Celgene; and is a consultant and speaker for Pfizer, American Regent and Takeda.

CHICAGO — The PROSPECT model predicted more than 80% of patients with Crohn’s disease have a moderate to high risk of developing related complications within 3 years of analysis, according to data presented at Digestive Disease Week.

“As we know, Crohn’s disease is a chronic, destructive disease that causes irreversible bowel damage in many patients,” Corey A. Siegel, MD, MS, from the Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, said during the presentation. “While damage typically happens early, there is a window of opportunity to prevent disease progression. We can get the right patients the right medications at the right time and we can prevent these complications from recurring over a period of time.”

Corey A. Siegel, MD, MS

Corey A. Siegel

The ongoing prospective study recruited 154 patients within 15 years of diagnosis of Crohn’s disease with no current or prior disease complications. Currently, 124 patients have been followed for 1 year. Median patient age is 31 years (range, 18-69 years) and 51% were women.

The PROSPECT tool uses serologic and genetic testing, disease phenotype and demographic information to generate an individualized risk profile. Patients either had a low risk of developing disease-related complication (17%), moderate risk (58%) or high risk (25%).

Twenty-one patients have experienced complications, including stricture (76%), internal penetrating (10%) or both (14%). Seven patients underwent surgery. Among the 21 patients with complications, 14% were considered low risk, 48% were considered moderate risk and 38% were considered high risk.

The study will continue for 2 years, at which time the researchers will explore how the PROSPECT tool influences patient decision making for Crohn’s disease therapy.  by Talitha Bennett

References:

Thompson KD, et al. Abstract 20. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.

Disclosure: Siegel reports he is a consultant for AbbVie, Amgen, Lilly, Janssen, Sandoz, UCB, Prometheus and Celgene; and is a consultant and speaker for Pfizer, American Regent and Takeda.

    See more from Digestive Disease Week